Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17620323 | 0.88 | BACE1 (0.45) | KMT2AMEN1BACE1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13348 | 0.85 | KMT2A (0.47) | KMT2AMEN1BACE1ALDH1A1SMN1; SMN2 | |
| SCHEMBL9686 | 0.81 | BACE1 (0.55) | KMT2AMEN1BACE1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14321942 | 0.80 | BACE1 (0.49) | KMT2AMEN1BACE1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14322028 | 0.75 | BACE1 (0.60) | KMT2AMEN1BACE1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14321923 | 0.74 | BACE1 (0.49) | KMT2AMEN1BACE1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14321711 | 0.74 | BACE1 (0.45) | KMT2AMEN1BACE1ALDH1A1SMN1; SMN2 | |
| SCHEMBL9381 | 0.71 | KMT2A (0.48) | KMT2AMEN1BACE1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11263 | 0.71 | HIF1A (0.36) | KMT2ABACE1ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL9661 | 0.69 | ALDH1A1 (0.44) | KMT2AALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2504315-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | KMT2A 1441/4885MEN1 4400/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.